A bispecific HER2/CD3 targeting FynomAb with excellent tumor killing and favorable pharmacokinetic properties

被引：0
|
作者：
Wuellner, Ulrich [1 ]
Buller, Fabian [1 ]
Klupsch, Kristina [1 ]
Brack, Simon [1 ]
Zbinden, Irene [1 ]
Santimaria, Roger [1 ]
Attinger-Toller, Isabella [1 ]
Koenig-Friedrich, Susann [1 ]
Bertschinger, Julian [1 ]
Grabulovski, Dragan [1 ]
机构：
[1] Covagen AG, Zurich, Switzerland
来源：
CANCER RESEARCH | 2014年 / 74卷 / 19期
关键词：
D O I：
10.1158/1538-7445.AM2014-656
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
656
引用
收藏
页数：1
相关论文
共 50 条
  • [21] HER2×CD3双抗体治疗过度表达HER2基因裸鼠乳腺癌及其机制
    任辉
    张研
    姜涛
    边学海
    郑泽霖
    中华实验外科杂志, 2005, (01) : 47 - 49
  • [22] Tri-specific CD3 x HER2 x HER2 antibodies in 1:2 format recognizing two different epitopes on HER2 demonstrate selective activity on human cancer cells with high HER2 expression
    Zhang, Jie
    Wang, Xiaoqing
    Zhou, Zhenhao
    CANCER RESEARCH, 2023, 83 (07)
  • [23] αHER2/CD3 bifunctional RNA engineered human T cells specifically eliminate HER2+gastric cancer
    Luo, F.
    Qian, J.
    Yang, J.
    Deng, Y.
    Zheng, X.
    Liu, J.
    Chu, Y.
    EUROPEAN JOURNAL OF IMMUNOLOGY, 2016, 46 : 12 - 12
  • [24] A novel bispecific antibody drug conjugate targeting HER2 and HER3 with potent therapeutic efficacy against breast cancer
    Zong, Hui-fang
    Li, Xi
    Han, Lei
    Wang, Lei
    Liu, Jun-jun
    Yue, Ya-li
    Chen, Jie
    Ke, Yong
    Jiang, Hua
    Xie, Yue-qing
    Zhang, Bao-hong
    Zhu, Jian-wei
    ACTA PHARMACOLOGICA SINICA, 2024, 45 (08) : 1727 - 1739
  • [25] Selection of CD3 affinity allows generation of T-cell redirecting bispecific antibodies with unique pharmacokinetic and biodistribution properties
    Haber, Lauric
    Olson, Kara
    Babb, Robert
    Kelly, Marcus
    Crawford, Alison
    Retter, Marc
    DiLillo, David
    Ullman, Erica
    Finney, Jennifer
    Canova, Lauren
    Pawashe, Arpita
    Chiu, Danica
    Vazzana, Kristin
    Ram, Priyanka
    Mohrs, Katja
    Dorvilliers, Amanda
    Xiao, Jenny
    Makonnen, Sosina
    Hickey, Carlos
    Arnold, Cody
    Giurleo, Jason
    Patel, Supriya
    Tavare, Richard
    Chen, Ya Ping
    Chen, Gang
    Olson, William
    Thurston, Gavin
    Lin, John Chia-Yang
    Hermann, Aynur
    Kirshner, Jessica
    Smith, Eric J.
    CANCER RESEARCH, 2020, 80 (16)
  • [26] PRECLINICAL CHARACTERIZATION OF D3L-001, A NOVEL BISPECIFIC ANTIBODY THAT ENHANCE PHAGOCYTOSIS AND ERADICATION OF HER2 POSITIVE SOLID TUMOR VIA HER2 AND CD47 DUAL BLOCKADE
    Rui, Haopeng
    Nie, Siwei
    Shao, Jiaxiang
    Yang, Xiaofeng
    Chen, Jiahao
    Wang, Jia
    Zheng, Zhiqiang
    Lu, Jingtao
    Wang, Allison
    Hong, Jin
    Chen, Xiaosong
    Shen, Kunwei
    Chen, George
    JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2022, 10 : A1431 - A1431
  • [27] Target arm affinities determine preclinical efficacy and safety of anti-HER2/CD3 bispecific antibody
    Staflin, Karin
    de Zafra, Christina L. Zuch
    Schutt, Leah K.
    Clark, Vanessa
    Zhong, Fiona
    Hristopoulos, Maria
    Clark, Robyn
    Li, Ji
    Mathieu, Mary
    Chen, Xiaocheng
    Johnston, Jennifer
    Low, Justin
    Ybarra, Ryan
    Slaga, Dionysos
    Yang, Jihong
    Ovacik, Meric
    Dybdal, Noel O.
    Totpal, Klara
    Junttila, Melissa R.
    Ellerman, Diego
    Lee, Genee
    Dennis, Mark S.
    Prell, Rodney
    Junttila, Teemu T.
    JCI INSIGHT, 2020, 5 (07)
  • [28] Anti-tumor activity in preclinical models utilizing a conditional bispecific redirected activation molecule (COBRA) targeting Her2
    Stringer, Bradley
    Chouitar, Johara
    Cerbone, Jacqualine
    Fortin, Sarah
    Ainbinder, Alina
    Kysilovsky, Cassie
    Scott, Brittany
    Banerjee, Antara
    CANCER RESEARCH, 2024, 84 (07)
  • [29] Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors
    Fiore Cattaruzza
    Ayesha Nazeer
    Milton To
    Mikhail Hammond
    Caitlin Koski
    Lucas Y. Liu
    V. Pete Yeung
    Deena A. Rennerfeldt
    Angela Henkensiefken
    Michael Fox
    Sharon Lam
    Kari M. Morrissey
    Zachary Lange
    Vladimir N. Podust
    Mika K. Derynck
    Bryan A. Irving
    Volker Schellenberger
    Nature Cancer, 2023, 4 : 485 - 501
  • [30] Precision-activated T-cell engagers targeting HER2 or EGFR and CD3 mitigate on-target, off-tumor toxicity for immunotherapy in solid tumors
    Cattaruzza, Fiore
    Nazeer, Ayesha
    To, Milton
    Hammond, Mikhail
    Koski, Caitlin
    Liu, Lucas Y. Y.
    Yeung, V. Pete
    Rennerfeldt, Deena A. A.
    Henkensiefken, Angela
    Fox, Michael
    Lam, Sharon
    Morrissey, Kari M. M.
    Lange, Zachary
    Podust, Vladimir N. N.
    Derynck, Mika K. K.
    Irving, Bryan A. A.
    Schellenberger, Volker
    NATURE CANCER, 2023, 4 (04) : 485 - +
12345